News

MediWound Ltd. (MDWD) CEO Ofer Gonen on Q2 2022 Results - Earnings Call Transcript

  • MediWound Ltd. (NASDAQ:MDWD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Bryan Bergin - Cowen Ryan Zimmerman - BTIG Arthur He - H.C.
    08/10/2022

MediWound Schedules Second Quarter 2022 Financial Results

  • Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET
    08/01/2022
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

MediWound Ltd. (MDWD) can hold. Click on Rating Page for detail.

The price of MediWound Ltd. (MDWD) is 1.42 and it was updated on 2022-10-06 13:00:23.

Currently MediWound Ltd. (MDWD) is in undervalued.

News
    
News

MediWound Ltd. (MDWD) CEO Sharon Malka on Q1 2022 Results - Earnings Call Transcript

  • MediWound Ltd. (NASDAQ:MDWD ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Monique Kosse - IR Sharon Malka - CEO Boaz Gur-Lavie - Chief Financial Officer Ofer Gonen - Board Member Lior Rosenberg - Chief Medical Officer Cyaandi R.
    Tue, May. 17, 2022

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

  • MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
    Tue, May. 17, 2022

MediWound Posts Promising EscharEx Data For Chronic Wounds

  • MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs).  The study met its primary and secondary endpoints and wound closure safety measurements.
    Thu, May. 12, 2022

MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022

  • YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 on Tuesday, May 17, 2022.
    Tue, May. 10, 2022

MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022

  • Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds
    Tue, Mar. 29, 2022
SEC Filings
SEC Filings

MediWound Ltd. (MDWD) - D

  • SEC Filings
  • 10/04/2022

MediWound Ltd. (MDWD) - SC 13D/A

  • SEC Filings
  • 09/26/2022

MediWound Ltd. (MDWD) - 424B5

  • SEC Filings
  • 09/22/2022

MediWound Ltd. (MDWD) - S-8

  • SEC Filings
  • 08/09/2022

MediWound Ltd. (MDWD) - SC 13D/A

  • SEC Filings
  • 07/01/2022

MediWound Ltd. (MDWD) - EFFECT

  • SEC Filings
  • 06/06/2022

MediWound Ltd. (MDWD) - CORRESP

  • SEC Filings
  • 06/01/2022

MediWound Ltd. (MDWD) - UPLOAD

  • SEC Filings
  • 05/31/2022

MediWound Ltd. (MDWD) - F-3

  • SEC Filings
  • 05/25/2022

MediWound Ltd. (MDWD) - SC 13D

  • SEC Filings
  • 03/17/2022

MediWound Ltd. (MDWD) - 20-F

  • SEC Filings
  • 03/17/2022

MediWound Ltd. (MDWD) - 424B5

  • SEC Filings
  • 03/03/2022

MediWound Ltd. (MDWD) - 424B3

  • SEC Filings
  • 03/02/2022

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 02/14/2022

MediWound Ltd. (MDWD) - SC 13G

  • SEC Filings
  • 02/02/2022

MediWound Ltd. (MDWD) - S-8

  • SEC Filings
  • 05/05/2021

MediWound Ltd. (MDWD) - 424B3

  • SEC Filings
  • 03/22/2021

MediWound Ltd. (MDWD) - 20-F

  • SEC Filings
  • 02/25/2021

MediWound Ltd. (MDWD) - SC 13G

  • SEC Filings
  • 02/16/2021

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 02/02/2021

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 06/09/2020

MediWound Ltd. (MDWD) - S-8

  • SEC Filings
  • 02/25/2020

MediWound Ltd. (MDWD) - 424B5

  • SEC Filings
  • 02/25/2020

MediWound Ltd. (MDWD) - 20-F

  • SEC Filings
  • 02/25/2020

MediWound Ltd. (MDWD) - SC 13G

  • SEC Filings
  • 02/06/2020

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 02/05/2020

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 01/28/2020

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 01/27/2020

MediWound Ltd. (MDWD) - EFFECT

  • SEC Filings
  • 04/22/2019

MediWound Ltd. (MDWD) - CORRESP

  • SEC Filings
  • 04/18/2019

MediWound Ltd. (MDWD) - CORRESP

  • SEC Filings
  • 04/12/2019

MediWound Ltd. (MDWD) - CT ORDER

  • SEC Filings
  • 04/09/2019

MediWound Ltd. (MDWD) - UPLOAD

  • SEC Filings
  • 04/08/2019

MediWound Ltd. (MDWD) - S-8

  • SEC Filings
  • 03/25/2019

MediWound Ltd. (MDWD) - F-3

  • SEC Filings
  • 03/25/2019

MediWound Ltd. (MDWD) - 20-F

  • SEC Filings
  • 03/25/2019

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 02/14/2019

MediWound Ltd. (MDWD) - SC 13G

  • SEC Filings
  • 02/14/2019

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 02/12/2019

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 02/11/2019

MediWound Ltd. (MDWD) - SC 13G/A

  • SEC Filings
  • 02/06/2019
Press Releases
StockPrice Release
More Headlines
News

MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript

  • MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript
  • 03/17/2022

MediWound (MDWD) Reports Q4 Loss, Misses Revenue Estimates

  • MediWound (MDWD) delivered earnings and revenue surprises of 6.25% and 2.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
  • 03/17/2022

MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

  • YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 17 2022.
  • 03/10/2022

MediWound to Present at Upcoming Investor Conferences in February

  • YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in February. Details for each is as follows:
  • 02/14/2022

MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers

  • MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for wound healing) of venous leg ulcers (VLUs).  The study randomized 120 patients, of which 119 patients were treated by either EscharEx (n=46), a gel vehicle (n=43), or a non-surgical standard-of-care consisting of either enzymatic or autolytic debridement (n=30).
  • 01/24/2022

MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call Transcript

  • MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call Transcript
  • 11/16/2021

MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates

  • MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 13.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
  • 11/16/2021

Earnings Preview For MediWound

  • MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2021-11-16. Here's what investors need to know before the announcement.
  • 11/15/2021

MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care

  • EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar
  • 10/04/2021

MediWound to Present at Upcoming Investor Conferences

  • YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following investor conferences during the month of September 2021.
  • 09/03/2021

Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript

  • Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript
  • 08/10/2021

MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates

  • MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 6.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
  • 08/10/2021

MediWound Reports Second Quarter Financial Results

  • Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year
  • 08/10/2021

MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021

  • YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the second quarter ended June 30, 2021 at 7:00 am Eastern Time on Tuesday, August 10, 2021.
  • 08/02/2021

MediWound: Disappointing Thus Far But Still A Strong Buy

  • MediWound: Disappointing Thus Far But Still A Strong Buy
  • 07/30/2021

MediWound: Adjusting My Strategy After NexoBrid CRL

  • MediWound: Adjusting My Strategy After NexoBrid CRL
  • 07/28/2021

MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer

  • MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC).  In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel.
  • 07/26/2021

MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

  • Data Expected End of 2021
  • 07/26/2021

MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients

  • MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns.  The 145-subject study met its three primary endpoints.
  • 07/20/2021

MDWD Stock Increases Over 15% Pre-Market: Why It Happened

  • The stock price of Mediwound Ltd (NASDAQ: MDWD) increased by over 15% pre-market. This is why it happened.
  • 07/20/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD

  • NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).
  • 07/18/2021

MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal

  • Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers
  • 07/09/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD

  • New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether MediWound and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
  • 07/05/2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD

  • NEW YORK, June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).
  • 06/29/2021

Why Shares Of MediWound And Vericel Fell On Tuesday

  • Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Biologics License Application. The FDA identified issues related to the Chemistry, Manufacturing, and Controls (CMC) section of the application and requested that MediWound provide additional CMC information.
  • 06/29/2021

FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop

  • Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal in adults with deep partial-thickness or full-thickness burns. The FDA identified issues related to the Chemistry, Manufacturing, and Controls (CMC) section of the application and requested that MediWound provide additional CMC information.
  • 06/29/2021

MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application

  • Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy
  • 06/29/2021

Best Penny Stocks To Buy Now? 7 To Watch This Week

  • What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?
  • 06/20/2021

MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study

  • Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021
  • 06/09/2021

MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2021 Results - Earnings Call Transcript

  • MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2021 Results - Earnings Call Transcript
  • 05/08/2021

MediWound: Managing A Position Ahead Of NexoBrid's PDUFA

  • MediWound is preparing for NexoBrid's PDUFA date that is scheduled in June of this year. If approved, NexoBrid will be entering a $200M TAM with numerous benefits over the standard-of-care.
  • 05/02/2021

Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for

  • MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 04/28/2021

MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021

  • YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2021 at 7:00 am Eastern Time on Wednesday, May 5, 2021.
  • 04/26/2021

MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds

  • Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time
  • 03/24/2021

MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2020 Results - Earnings Call Transcript

  • MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2020 Results - Earnings Call Transcript
  • 02/28/2021

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

  • MediWound (MDWD) delivered earnings and revenue surprises of 45.45% and 19.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
  • 02/25/2021

MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer

  • Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021
  • 02/22/2021

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

  • MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 02/18/2021

MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021

  • YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2020 at 7:00 am Eastern Time on Thursday, February 25, 2021.
  • 02/16/2021

MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

  • YAVNE, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021.
  • 02/10/2021

7 Penny Stocks That Actually Have Buy Ratings

  • Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.
  • 02/03/2021

MediWound Provides Progress Update on Its EscharEx Clinical Development Program

  • Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients
  • 01/11/2021

MediWound to Participate in Upcoming Investor Conferences in January

  • YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it will participate in the forthcoming LifeSci Partners 10th Annual Corporate Access Event and the H.C. Wainwright BioConnect 2021 Conference. Both conferences will take place virtually.
  • 01/05/2021

MediWound: A Collectable Investment Worthy Of A Long-Term Hold

  • MediWound recently reported an encouraging Q3 with a beat on EPS and revenue. It looks as if the company is easily weathering the pandemic with support from BARDA purchases. I have already established a speculative position ahead of a potential NexoBrid approval. Now, I am looking to stick my MDWD in the back of my sock drawer.
  • 12/22/2020

Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent

  • Data to be Published in a Peer-Reviewed Journal in First Half 2021 Data to be Published in a Peer-Reviewed Journal in First Half 2021
  • 12/21/2020

MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group

  • YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year.
  • 12/14/2020

MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2020 Results - Earnings Call Transcript

  • MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2020 Results - Earnings Call Transcript
  • 11/10/2020

MediWound: Q3 Earnings Insights

  • Shares of MediWound (NASDAQ:MDWD) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share rose 36.36% over the past year to ($0.07), which beat the estimate of ($0.10).
  • 11/10/2020

MediWound Reports Third Quarter 2020 Financial Results

  • Total Third Quarter R evenues of $6.6 Million Increased 29 % Y ear-over- Y ear
  • 11/10/2020

MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020

  • YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 at 7:00 am Eastern Time on Tuesday, November 10, 2020.
  • 11/02/2020

MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study

  • Top-line Data is Expected in the Second Half of 2021 Top-line Data is Expected in the Second Half of 2021
  • 10/28/2020

MediWound: An Underfollowed Opportunity At A Discount

  • MediWound has popped up on my scanner multiple times over the past few years but the conditions never lined up for me to establish a position.
  • 09/08/2020

MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates

  • MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and -15.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
  • 08/06/2020

MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  • Submitted Biological License Application to the FDA for NexoBrid  EscharEx U.S. Phase 2 Study Resumed Patient ScreeningYAVNE, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced financial results for the second quarter ended June 30, 2020 and provided business and financial updates related to the COVID-19 pandemic. Second Quarter Business and Financial Highlights: * Revenues for the second quarter of 2020 were $4.0 million, compared with $20.7 million for the second quarter of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement   * The Company had $24.4 million in cash and short-term investments as of June 30, 2020, compared with $29.5 million as of December 31, 2019   * Resumed patient screening and randomization in U.S. EscharEx® phase 2 adaptive design study for the treatment of venous leg ulcers (“VLU’s”); Interim assessment is anticipated in the first half of 2021   * Submitted Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for NexoBrid® for the treatment of severe thermal burns in adults   * Instituted a series of measures to address challenges associated with the COVID-19 pandemic, while maintaining workforce and operational capacity and flexibility“We are pleased to have submitted the BLA for NexoBrid on schedule despite the disruptions of the COVID-19 pandemic. This submission is a major milestone in our long-term partnership with BARDA, and we are actively preparing for the commercial launch with our partner, Vericel, upon approval,” said Sharon Malka, Chief Executive Officer of MediWound. “In addition, we are actively recruiting and enrolling patients in our U.S. EscharEx phase 2 study, and we are encouraged to see progress in moving this trial forward.”Mr. Malka concluded, “In recent months, humanity is facing tremendous challenges with a great deal of uncertainty. We are privileged to be among those tasked with improving patients’ quality of care and impacting their lives. Our solid balance sheet continues to support our growth as we execute on our strategic plans, and we are optimistic that we will continue to successfully strengthen our Company.”Corporate UpdateMediWound has implemented several measures to safeguard the health and well-being of its employees, their families, and healthcare providers. The Company has reduced expenses to minimize impact to operations while ensuring full compliance with all necessary regulations. Management continues to assess the impact of the pandemic, the potential implications to business continuity, and necessary remedies and will adjust accordingly to the challenges created by any directives from regulatory authorities.The Company continues to manufacture and supply NexoBrid to patients with severe burn injuries, including manufacturing NexoBrid and building an emergency stockpile for the U.S. Biomedical Advanced Research and Development Authority (BARDA), while the first delivery to BARDA is planned in the third quarter of 2020. The Company maintains a significant safety stock of all key raw materials and NexoBrid inventory to meet expected demand over the next several quarters. At this time, the Company does not expect any disruptions to its manufacturing operations and global supply chain. The Company submitted a BLA to the U.S. FDA seeking the approval of NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and full-thickness thermal burns. The BLA submission is based on multiple preclinical and clinical studies including the pivotal Phase 3 U.S. clinical study (DETECT) of NexoBrid in adult patients with severe thermal burns. Vericel Corporation (NASDAQ: VCEL) holds an exclusive license for North American commercial rights of NexoBrid. MediWound is eligible to receive a $7.5 million milestone payment from Vericel upon BLA approval. On the clinical front, the Company has resumed new patients’ screening and randomization in its U.S. EscharEx phase 2 adaptive design study for the treatment of VLU’s and expects to achieve the pre-defined interim assessment in the first half of 2021. In addition, enrollment in the NexoBrid expanded access (NEXT) program continues with enhanced safety measures, such as remote visits and virtual tools.The Company had $24.4 million in cash and short-term investments as of June 30, 2020, compared with $29.5 million as of December 31, 2019, with no debt. The Company reiterates its expectations of cash use for operating activities in 2020 to be in the range of $8 to $10 million.  At this time, the Company cannot predict the extent or duration of the impact of the COVID-19 outbreak on its ongoing financial and operational results.Second Quarter Financial ResultsRevenues for the second quarter of 2020 were $4.0 million, compared with $20.7 million for the second quarter of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement. Revenues from product in the second quarter of 2020 were $1.1 million, reflecting an increase of 17% in comparison to the second quarter of 2019, excluding the one-time upfront payment.Gross profit for the second quarter of 2020 was $1.2 million, compared to a gross profit of $17.5 million for the second quarter of 2019, which included $16.8 million from the Vericel licensing agreement. Research and development expenses for the second quarter of 2020, net of participations, were $1.6 million, compared with $0.4 million for the second quarter of 2019. The increase was primarily due to decrease of participation by BARDA and Israeli Innovation Authority (IIA).  Selling, general and administrative expenses for the second quarter of 2020 were $2.3 million, in line with the second quarter of 2019.Operating loss for the second quarter of 2020 was $2.7 million, compared with an operating profit of $13.9 million in the second quarter of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement, net of royalty payment of $0.7 million and $0.8 million of other expenses. The Company posted a net loss of $3.1 million, or $0.11 per share, for the second quarter of 2020 compared with a net profit of $12.7 million, or $0.47 per share, for the second quarter of 2019, which included the $17.5 million upfront license payment, net of royalty payment of $0.7 million and $0.8 million of other expenses. Excluding the upfront license payment net of deal related costs, net loss for the second quarter of 2019 was $3.3 million, or $0.12 per share.Adjusted EBITDA, as defined below, for the second quarter of 2020 was a loss of $2.1 million, compared with a profit of $15.4 million for the second quarter of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement, net of royalty payment of $0.7 million.                                                  Year-to-Date 2020 Financial ResultsRevenues for the first half of 2020 were $8.5 million compared with $21.2 million in the first half of 2019, which included the $17.5 million upfront payment from the Vericel licensing agreement for NexoBrid.The Company’s net loss for the first half of 2020 was $5.6 million or  $0.20 per share compared with net profit of $8.6 million or  $0.32 per share for the first half of 2019, which included the $17.5 million upfront license payment, net of royalty payment of $0.7 million and $0.9 million of other expenses. Excluding the upfront license payment net of deal related costs, net loss for the first half of 2019 was $7.3 million, or $0.27 per share.Adjusted EBITDA, for the first half of 2020, was a loss of $3.9 million, compared with a profit of $12.4 million for the first half of 2019, which included the upfront payment of $17.5 million from the Vericel licensing agreement, net of royalty payment of $0.7 million. Conference CallMediWound management will host a conference call for investors today, Thursday, August 6, 2020 beginning at 8:30 a.m. Eastern Time to discuss these results and answer questions.  Shareholders and other interested parties may participate in the conference call by dialing 877-602-7189 (in the U.S.)  1809 315 362 (Israel), or 678-894-3057 (outside the U.S. & Israel) and entering passcode 3176168. The call also will be webcast live on the Company’s website at http://ir.mediwound.com/events-and-presentations.A replay of the call will be accessible two hours after its completion through August 27, 2020 by dialing 855-859-2056 (in the U.S.) or 404-537-3406 (outside the U.S.) and entering passcode 3176168. The call will also be archived on the Company website for 90 days at www.mediwound.com.About MediWound Ltd.MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue. The product has received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health. MediWound’s second innovative product, EscharEx® is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid. In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com.
  • 08/06/2020

Should MediWound (NASDAQ:MDWD) Be Disappointed With Their 52% Profit?

  • The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...
  • 07/31/2020

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

  • MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 07/30/2020

MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020

  • YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 at 7:00 am Eastern Time on Thursday, August 6, 2020. Following the release, MediWound's management will host a conference call and live webcast on Thursday, August 6, 2020 at 8:30 am Eastern Time to discuss the financial results and to answer questions. Dial-in and call details are as follows:Conference Call & Webcast Details  Toll-Free:877-602-7189 Israel Toll-Free:1 809 315 362 International:678-894-3057 Conference ID:3176168 Webcast:https://edge.media-server.com/mmc/p/jt3zx63y To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.  An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.About MediWound Ltd. MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue. The product has received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health. MediWound’s second innovative product, EscharEx® is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid.  In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.  For more information, please visit www.mediwound.com.Contacts:  Boaz Gur-Lavie Jeremy Feffer Chief Financial OfficerManaging Director MediWound Ltd.LifeSci Advisors, LLC ir@mediwound.com jeremy@LifeSciAdvisors.com
  • 07/28/2020

MediWound (MDWD) Jumps: Stock Rises 9.4%

  • MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
  • 07/14/2020

MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns

  • MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the approval of NexoBrid® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. The BLA submission includes a comprehensive set of manufacturing data, multiple preclinical and clinical studies including the pivotal U.S. Phase 3 (DETECT) study of NexoBrid in adult patients with deep partial and full-thickness thermal burns up to 30% of total body surface area.
  • 06/30/2020

Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers

  • Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers
  • 05/27/2020

4 Profitable Stocks to Boost Returns Using Net Income Ratio

  • Investors always look for companies with a high level of profitability regardless of the present market condition.
  • 05/26/2020

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

  • MediWound (MDWD) delivered earnings and revenue surprises of 35.71% and 4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
  • 05/20/2020

MediWound shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

  • 05/20/2020

30 Stocks Moving in Wednesday's Pre-Market Session

  • 05/20/2020

Recap: MediWound Q1 Earnings

  • Shares of MediWound (NASDAQ:MDWD) moved higher by 6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 40.00% over the past year to ($0.09), which beat the estimate of ($0.14).Revenue of $4,438,000 up by 862.69% year over year, which beat the estimate of $4,050,000.Outlook MediWound hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 20, 2020View more earnings on MDWDTime: 08:30 AMET Webcast URL: https://mediwound.gcs-web.com/events-and-presentationsRecent Stock Performance 52-week high: $4.6552-week low: $1.44Price action over last quarter: down 13.33%Company Overview MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from United States.See more from Benzinga * McKesson: Q4 Earnings Insights * Recap: Lowe's Companies Q1 Earnings * ShiftPixy: P/E Ratio Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
  • 05/20/2020

MediWound Q1 EPS $(0.090) Beats $(0.140) Estimate, Sales $4.400M Beat $4.050M Estimate

  • 05/20/2020

MediWound Reports First Quarter 2020 Financial Results and Provides Corporate Update

  • YAVNE, Israel, May 20, 2020 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs.
  • 05/20/2020

MediWound Ltd. to Host Earnings Call

  • NEW YORK, NY / ACCESSWIRE / May 20, 2020 / MediWound Ltd. (NASDAQ:MDWD) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 20, 2020 at 8:30 AM Eastern ...
  • 05/20/2020

The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

  • Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ADC Therapeutics SA (NYSE:...
  • 05/20/2020

The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows

  • Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online ...
  • 05/17/2020

MediWound to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 20, 2020

  • YAVNE, Israel, May 13, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.
  • 05/13/2020

MediWound to Report First Quarter —…—… Financial Results and Host a Conference Call and ...

  • 05/13/2020

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

  • MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 05/12/2020

Sargent Investment Group, LLC Buys Iron Mountain Inc, LivePerson Inc, Visa Inc, Sells Universal ...

  • 05/12/2020

MediWound Announces Distributin Agreements For NexoBrid

  • 05/04/2020

MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements

  • MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced the expansion of its NexoBrid® European presence with distribution agreements granting GENFA MEDICA SA, its distributer in Russia, Ukraine and the Baltic countries, the exclusive right to market and distribute NexoBrid in France and Switzerland and Specialty Therapeutics PC the exclusive right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus. NexoBrid, currently approved in the European Union and other international markets, is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns.
  • 05/04/2020

MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements

  • 05/04/2020

MediWound Ltd.'s (NASDAQ:MDWD) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

  • It is hard to get excited after looking at MediWound's (NASDAQ:MDWD) recent performance, when its stock has declined...
  • 05/02/2020

MediWound Strengthens Board of Directors

  • MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointments of Mr. Samuel Moed and Mr. David Fox to its Board of Directors to serve until the 2020 annual meeting of shareholders
  • 04/27/2020

MediWound Strengthens Board of Directors

  • 04/27/2020

Vericel to Report First-Quarter 2020 Financial Results on May 5, 2020

  • CAMBRIDGE, Mass., April 22, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the.
  • 04/22/2020

Vericel Announces Change to a Virtual Meeting Format For 2020 Annual Meeting of Shareholders

  • Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that as a result of the COVID-19 pandemic, to support the health and well-being of our employees and shareholders, and to comply with state stay-at-home orders, including the
  • 04/10/2020

Vericel to Present at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, 2020

  • CAMBRIDGE, Mass., April 08, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
  • 04/08/2020

The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

  • Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) * BIOLASE Inc (NASDAQ: BIOL) * BioNano Genomics Inc (NASDAQ
  • 04/03/2020

The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

  • Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ:...
  • 04/03/2020

Vericel Provides Business and Financial Updates

  • First Quarter Preliminary Unaudited Product Revenues Increased Approximately 21% Over First Quarter 2019 Full Year 2020 Financial Guidance Withdrawn Due to Uncertainty.
  • 04/02/2020

Gone To Pot

  • Here are a few marijuana stocks to see how
  • 03/31/2020

Gone To Pot

  • 03/31/2020

MediWound Provides Corporate Update Related to COVID-19 Pandemic

  • MediWound Ltd. (MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on certain impacts of the COVID-19 pandemic on its business operations and clinical programs. At the same time, the Company is working to ensure that healthcare providers and patients have uninterrupted access to our commercial and products under development. The Company has instituted a global remote work policy and is now leveraging virtual tools and digital communication technologies to continue important interactions with its employees, healthcare professionals, patients and other stakeholders.
  • 03/30/2020

MediWound Provides Corporate Update Related to COVID-–9 Pandemic

  • 03/30/2020

108 Biggest Movers From Yesterday

  • Gainers Cypress Semiconductor Corporation (NASDAQ: CY) shares jumped 48.9% to close at $22.75 on Tuesday after the company received clearance from the Committee on Foreign...
  • 03/11/2020

82 Stocks Moving In Tuesday's Mid-Day Session

  • Gainers Cypress Semiconductor Corporation (NASDAQ: CY) climbed 45.8% to $22.28 after the company received clearance from the Committee on Foreign Investment in the United States...
  • 03/10/2020

The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

  • Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
  • 03/10/2020

Edited Transcript of MDWD earnings conference call or presentation 25-Feb-20 1:30pm GMT

  • Q4 2019 Mediwound Ltd Earnings Call
  • 03/10/2020

Edited Transcript of VCEL earnings conference call or presentation 25-Feb-20 1:30pm GMT

  • Q4 2019 Vericel Corp Earnings Call
  • 03/05/2020
Unlock
MDWD Ratings Summary
MDWD Quant Ranking